Auteurs
Curation
Istex
Racine
Curation
Checkpoint
Istex
Racine
Istex
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Curation (Istex)

Index « Auteurs » - entrée « H. Yamanaka »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
H. Yamamoto < H. Yamanaka < H. Yamazaki  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 12.
Ident.Authors (with country if any)Title
000438 (2013) E. Tanaka [Japon] ; E. Inoue [Japon] ; D. Hoshi [Japon] ; A. Kobayashi [Japon] ; N. Sugimoto [Japon] ; K. Shidara [Japon] ; E. Sato [Japon] ; Y. Seto [Japon] ; A. Nakajima [Japon] ; S. Momohara [Japon] ; A. Taniguchi [Japon] ; H. Yamanaka [Japon]AB0528 Cost-effectiveness of a humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, tocilizumab, in rheumatoid arthritis using IORRA cohort database
000581 (2013) T. Takeuchi [Japon] ; Y. Tanaka ; K. Amano ; J. Kikuchi [Japon] ; E. Tanaka [Japon] ; S. Hirata ; H. Nagasawa ; H. Yasuoka [Japon] ; H. Yamanaka [Japon]SAT0140 Effectiveness of Abatacept Against Rheumatoid Arthritis in Daily Clinical Practice - Orbit Study
000678 (2013) Y. Tanaka ; T. Takeuchi [Japon] ; K. Amano ; E. Sato [Japon] ; M. Nawata ; H. Nagasawa ; D. Hoshi [Japon] ; K. Saito ; S. Fukuyo ; K. Hanami ; H. Kameda [Japon] ; T. Kurasawa ; Y. Kaneko [Japon] ; H. Yamanaka [Japon]AB0586 104-weeks assessments of clinical and structural remission in rheumatoid arthritis patients with tocilizumab from the reaction study
000763 (2013) H. Yamanaka ; M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu [Japon] ; S. Takei ; T. Takeuchi [Japon] ; Y. Tanaka ; Y. Sano [Japon] ; T. Koike [Japon]THU0092 The advantage of early intervention by tocilizumab for rheumatoid arthritis - full analysis of all-case postmarketing surveillance in 7,901 patients in japan
000772 (2013) E. Tanaka [Japon] ; E. Inoue [Japon] ; D. Hoshi [Japon] ; K. Shidara [Japon] ; E. Sato [Japon] ; Y. Inoue [Japon] ; Y. Seto [Japon] ; A. Nakajima [Japon] ; S. Momohara [Japon] ; A. Taniguchi [Japon] ; H. Yamanaka [Japon]AB0308 Optimal timing for tocilizumab administration to patients with rheumatoid arthritis in japan based on a cost-effectiveness analysis using the iorra cohort study
000804 (2013) T. Takeuchi [Japon] ; Y. Kaneko [Japon] ; T. Atsumi ; Y. Tanaka ; M. Inoh ; H. Kobayashi [Japon] ; K. Amano ; M. Miyata ; Y. Murakawa ; T. Fujii ; A. Kawakami ; H. Yamanaka ; K. Yamamoto ; N. Miyasaka [Japon] ; T. MimoriOP0040 Adding Tocilizumab or Switching to Tocilizumab Monotherapy in RA Patients with Inadequate Response to Methotrexate: 24-Week Results from a Randomized Controlled Study (Surprise Study)
000999 (2013) M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu ; T. Takeuchi [Japon] ; S. Takei ; Y. Tanaka ; H. Yamanaka ; Y. Sano [Japon] ; H. Yaguramaki [Japon] ; T. Koike [Japon]SAT0120 Characteristics Associated with Better Effectiveness and Safety in Rheumatoid Arthritis Patients Treated with Intravenous Tocilizumab: Results from Full Analysis of All-Patient Postmarketing Surveillance in Japan
000B86 (2013) Y. Shimizu [Japon] ; E. Tanaka [Japon] ; E. Inoue [Japon] ; K. Shidara [Japon] ; D. Hoshi [Japon] ; N. Sugimoto [Japon] ; E. Sato [Japon] ; Y. Seto [Japon] ; S. Momohara [Japon] ; A. Nakajima [Japon] ; A. Taniguchi [Japon] ; H. Yamanaka [Japon]FRI0096 Influence of dose titration of concomitant steroid and methotrexate during biologic therapy on remission rates in patients with rheumatoid arthritis according to the new ACR/EULAR remission criteria in daily practice based on the iorra cohort
000C06 (2013) Y. Tanaka ; M. Harigai ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Yamamoto [Japon] ; M. Kanazawa ; Y. Murakami ; T. Yoshinari [Japon] ; D. Baker [États-Unis] ; N. Miyasaka ; T. Koike [Japon]FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy
000C84 (2013) Y. Tanaka ; K. Yamamoto [Japon] ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Eguchi ; A. Watanabe [Japon] ; H. Origasa ; T. Okamoto ; T. Shoji ; N. Miyasaka [Japon] ; T. Koike [Japon]AB0294 Long-term comprehensive disease control with certolizumab pegol regardless of concomitant dmards: results from the japanese cohort
000D61 (2013) K. Ochi [Japon] ; E. Tanaka [Japon] ; K. Shidara [Japon] ; K. Ikari [Japon] ; A. Nakajima [Japon] ; A. Taniguchi [Japon] ; S. Momohara [Japon] ; H. Yamanaka [Japon]FRI0065 Clinical factors associated with the progression of functional impairment in rheumatoid arthritis patients who maintained the remission criteria defined by the new acr/eular criteria
000F04 (2013) K. Shidara [Japon] ; A. Nakajima [Japon] ; E. Inoue [Japon] ; D. Hoshi [Japon] ; E. Tanaka [Japon] ; Y. Inoue [Japon] ; A. Kobayashi [Japon] ; Y. Seto [Japon] ; S. Momohara [Japon] ; A. Taniguchi [Japon] ; H. Yamanaka [Japon]FRI0068 Sustaining remission as defined by the new acr/eular criteria leads to better quality of life in patients with rheumatoid arthritis

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/Author.i -k "H. Yamanaka" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/Author.i  \
                -Sk "H. Yamanaka" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    Author.i
   |clé=    H. Yamanaka
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021